866-997-4948(US-Canada Toll Free)

Malignant Neoplasms - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 75 Pages


Global Markets Directs, \'Malignant Neoplasms Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Malignant Neoplasms, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Neoplasms. 

Malignant Neoplasms Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Malignant Neoplasms.
  • A review of the Malignant Neoplasms products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Malignant Neoplasms pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Malignant Neoplasms.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Malignant Neoplasms pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Malignant Neoplasms Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Malignant Neoplasms 9
Malignant Neoplasms Therapeutics under Development by Companies 11
Malignant Neoplasms Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Malignant Neoplasms Therapeutics - Products under Development by Companies 18
Malignant Neoplasms Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in Malignant Neoplasms Therapeutics Development 21
F. Hoffmann-La Roche Ltd. 21
Kyowa Hakko Kirin Co., Ltd. 22
Shionogi & Co., Ltd. 23
Amgen Inc. 24
Sanofi-Aventis 25
Genentech, Inc. 26
Enzon Pharmaceuticals, Inc. 27
Bayer AG 28
Cytomedix, Inc. 29
Antisense Pharma GmbH 30
INNOPHARMAX, INC. 31
Etubics Corporation 32
Kyowa Hakko Kirin Pharma, Inc. 33
Malignant Neoplasms - Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
PEG-SN38 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
RG-7112 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SAR-405838 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
S-222611 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ETBX-011 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BAY-1000394 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
firtecan pegol + [bevacizumab] - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
KHK-2866 + [carboplatin] + [gemcitabine hydrochloride] - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
KHK-2866 + [paclitaxel] - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
KHK-2866 + [doxorubicin] 55
- Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KHK-2866 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
conatumumab + [bevacizumab] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
NCE For Neoplasms - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
TriN-2755 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
SGT-94 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SMP-105 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MPDL-3280A + Zelboraf - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
gemcitabine hydrochloride Oral - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
SAR-260301 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ALD-451 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Malignant Neoplasms Therapeutics - Drug Profile Updates 70
Malignant Neoplasms Therapeutics - Dormant Products 73

Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Table


Number of Products Under Development for Malignant Neoplasms, H1 2013 9
Products under Development for Malignant Neoplasms - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Development by Companies, H1 2013 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Development by Companies, H1 2013 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2013 20
F. Hoffmann-La Roche Ltd., H1 2013 21
Kyowa Hakko Kirin Co., Ltd., H1 2013 22
Shionogi & Co., Ltd., H1 2013 23
Amgen Inc., H1 2013 24
Sanofi-Aventis, H1 2013 25
Genentech, Inc., H1 2013 26
Enzon Pharmaceuticals, Inc., H1 2013 27
Bayer AG, H1 2013 28
Cytomedix, Inc., H1 2013 29
Antisense Pharma GmbH, H1 2013 30
INNOPHARMAX, INC., H1 2013 31
Etubics Corporation, H1 2013 32
Kyowa Hakko Kirin Pharma, Inc., H1 2013 33
Assessment by Monotherapy Products, H1 2013 34
Assessment by Combination Products, H1 2013 35
Assessment by Stage and Route of Administration, H1 2013 37
Assessment by Stage and Molecule Type, H1 2013 39
Malignant Neoplasms Therapeutics - Drug Profile Updates 70
Malignant Neoplasms Therapeutics - Dormant Products 73

List of Chart


Number of Products under Development for Malignant Neoplasms, H1 2013 9
Products under Development for Malignant Neoplasms - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 34
Assessment by Combination Products, H1 2013 35
Assessment by Route of Administration, H1 2013 36
Assessment by Stage and Route of Administration, H1 2013 37
Assessment by Molecule Type, H1 2013 38
Assessment by Stage and Molecule Type, H1 2013 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *